2023年7月11日

三星生物製劑已經記錄下上半年的訂單首席執行官約翰•Rim 2023.07.11 13:31:01 | 2023.07.11 13:48:11接收機三星生物製劑有限公司首席執行官約翰Rim(照片由三星提供生物製劑)韓國三星生物製劑有限公司首席執行官約翰•Rim看到其累計訂單金額達到創紀錄的2.34萬億韓元的今年前六個月。分析人士說,約翰Rim的活躍的全球首席執行官現場管理和全球銷售中心已導致大量訂單。據業內消息人士周一,約翰Rim花了大約30天今年上半年的討論合作與全球製藥公司在美國和歐洲。從2023年摩根大通醫療會議在舊金山1月初,他參與重大事件在製藥和生物技術行業,包括DCAT本周在紐約在2023年3月和theBIO美國6月在波士頓。在這些事件中,約翰Rim專注於建立一個強大的網絡與製藥高管。今年5月,他還參加了一係列會議三星電子有限公司執行董事長李在鎔舉行的首席執行官五大全球製藥公司在美國探索新的商機,目的是促進生物業務第二半導體在集團層麵。的ceo會議包括華金Duato強生(Johnson & Johnson)(強生),喬凡尼Caforio百時美施貴寶公司有限公司(BMS), Noubar Afeyan旗艦先驅,魏巴赫生原體Inc .和凱文·阿裏的工具論& Co .在會議期間,約翰•Rim公司的代表不僅集團還國內製藥和生物產業,據報道合作的項目提供了寶貴的意見。約翰Rim之前在瑞士羅氏製藥公司股價和Genentech公司工作,2018年9月加入三星生物製劑在2020年12月成為首席執行官。在短短一年的辦公室,他公司的銷售和營業利潤增加了35%和84%,分別。去年,三星生物製劑達到3萬億韓元的銷售和營業利潤為1萬億韓圓,成為國內第一個達到這個裏程碑的製藥和生物技術公司。 He has been praised for achieving rapid growth based on a precise understanding of the bio industry. Earlier this year, concerns arose about Samsung Biologics’ overseas business as the departure of the head of the Global Sales Center without an expert to lead its overseas activities. To address the issue, John Rim took matters into his own hands. He personally took on the role of the head of the center. He also began serving as the chairman of the board of directors in March to expedite decision-making. Global pharmaceutical companies such as J&J, BMS, and Merck & Co. Inc. all have CEOs who also chair their boards of directors to efficiently manage their businesses. John Rim’s active involvement in managing overseas operations is being reflected in actual performance. Samsung Biologics announced on Monday that it has signed a contract manufacturing organization (CMO) deal worth 511.1 billion won ($395.19 million) with Novartis AG, the world’s fifth-largest pharmaceutical company. The volume, which was originally valued at 100.5 billion won when the company signed a letter of intent (LOI) in June last year, has increased to 405.2 billion won based on high trust built in the process leading to the main contract a year later and was finalized at a total of 511.1 billion won. Additionally, last week, the company inked a CMO contract worth around 1.2 trillion won with Pfizer Inc, a U.S. multinational pharmaceutical and biotechnology company. With aggressive marketing, excellent quality control capabilities, and superior production speed that surpasses its competitors, Samsung Biologics has continuously secured additional volumes in less than a week. By Shim Hee-jin and Yoon Yeon-hae [ⓒ Pulse by Maeil Business News Korea & mk.co.kr, All rights reserved] TUE